Epicrispr Biotechnologies (“Epicrispr”), a clinical-stage company pioneering gene-modulating therapies, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of the ...
ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company specializing in treatments for rare and muscular diseases, is poised to redefine Central Nervous System (CNS) drug delivery with its ...
Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised ...
The American College of Sports Medicine released new guidelines this year to help doctors prescribe resistance exercise. Here ...
At Sarepta Therapeutics, we’ve seen it all. Here are the questions I believe we should be asking to move forward in Duchenne muscular dystrophy.
Have the Bears been hinting at their plan for the pass rush the whole offseason? @thechicagosares with more on it below.
IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month ...
Struggling Greater Union Baptist Church sits on the north edge of the area targeted in a $7 billion plan to convert acres of ...
The Phase 1/2 FUNCTION-DMD study will enroll ambulatory patients and is designed to evaluate safety, tolerability, and efficacy, including dystrophin protein expression and functional outcomes. "The ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® ...
Enters into Strategic Transaction, unlocking $100 million in value Sharpens focus on Orphan Drug candidates to address unmet medical needs NASHVILLE, Tenn., May 5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results